The Study On Neuroprotective Biomarkers Of Parkinson’s Disease Based On EEG Source Analysis

Parkinson’s disease(PD)is one of the most common neurodegenerative disorders,which has a serious effect on the normal work and life of patients.The quest for neuro-protection in PD has been for new compounds to slow disease progression and stable and non-invasive biomarkers to document their benefits.NeuroEPO is a kind of glycoprotein hormone.In recent years,studies have shown that NeuroEPO plays a wide role in the process of neuron repair and regeneration,and it reported good results in animal models and tolerance in healthy participants.25 PD patients were assigned randomly to NeuroEPO(n=15)or placebo(n=10)groups.Resting state electroencephalography(EEG)was recorded before and 6 months after administration of the drug.We used the Grand Total EEG score(GTE)and multidi-mensional item response theory to conduct qualitative EEG analysis.In addition,Variable Resolution Electromagnetic Tomographic Analysis(VARETA)and linear mixed effect model were applied for quantitative EEG analysis.Based on the above EEG analysis,we combined with the cognitive scale data of PD patients to build a mediation model.We tried to explore the relationship between EEG changes and cognitive function in patients with PD.In this paper,the neuroprotective effect of NeuroEPO on PD patients was explored through multiple perspectives.After the administration of the drug,the results of qualitative EEG analysis showed that the NeuroEPO group had fewer EEG abnormalities than the placebo group(p=0.009).Quantitative EEG analysis showed that there was a decrease of delta rhythm in the opercu-lar part of the inferior frontal gyrus in the left hemisphere,an increment of alpha rhythm in central,frontal and parieto-temporal areas and a decrease of beta rhythm in fronto-orbital,temporal and limbic structures for the NeuroEPO group from baseline to 6 months after intervention relative to the placebo group.The results of mediation analysis showed that there was a mediation effect in our model(p<0.001).As a mediator,EEG mediated the relationship between the treatment and cognitive function of patients with PD.That is to say,NeuroEPO first affected the EEG of PD patients,and then the changes of EEG had an impact on their cognitive function.Our study found that even a small dose of NeuroEPO can reduce EEG abnormali-ties in PD patients,indicating that NeuroEPO has an effect on neural circuitries related to generators of the brain rhythms.Our paper provided concurrent validation between qualitative and quantitative EEG analysis,and the results showed that these two analysis methods could discriminated between PD patients who received NeuroEPO or placebo.The results of this study showed that NeuroEPO has neuroprotective effect on patients with PD,and may become a potential drug for the treatment of PD in the future,which has great research value.